Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 128

Sort by

Sort Order Select

Journal Articles

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Blood (2025) 146 (3): 291–303.

https://doi.org/10.1182/blood.2024028064

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Blood (2019) 133 (26): 2765–2775.

https://doi.org/10.1182/blood-2019-01-896290

Published: 2019

Includes: Supplemental data

Journal Articles

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Susan O’Brien, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, William Wierda, Jeffrey Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd

Blood (2018) 131 (17): 1910–1919.

https://doi.org/10.1182/blood-2017-10-810044

Published: 2018

Includes: Supplemental data

Journal Articles

Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience

Kamal Chamoun, MD, Hagop M. Kantarjian, MD, Mary Abisola Akosile, PhD, Rita Assi, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Marina Konopleva, MD PhD, Zeev Estrov, MD, Courtney D. DiNardo, MDMSc, Naval Daver, MD, Naveen Pemmaraju, MD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, William Wierda, MD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1594.

https://doi.org/10.1182/blood.V130.Suppl_1.1594.1594

Published: 2017

Journal Articles

Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment

Ghayas C. Issa, Hagop M. Kantarjian, Graciela Nogueras Gonzalez, Gautam Borthakur, Guilin Tang, William Wierda, Koji Sasaki, Nicholas J. Short, Farhad Ravandi, Tapan Kadia, Keyur Patel, Raja Luthra, Alessandra Ferrajoli, Guillermo Garcia-Manero, Mary Beth Rios, Sara Dellasala, Elias Jabbour, Jorge E. Cortes

Blood (2017) 130 (19): 2084–2091.

https://doi.org/10.1182/blood-2017-07-792143

Published: 2017

Includes: Supplemental data

Journal Articles

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

Blood (2017) 129 (10): 1275–1283.

https://doi.org/10.1182/blood-2016-09-736686

Published: 2017

Journal Articles

Solid Tumors in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Lenalidomide Therapy: Distribution and Clinical Outcomes

Ahmad Alhuraiji, MD MRCP, Lorenzo Falchi, MD, Michael Keating, MBBS, Zeev Estrov, MD, Paolo Strati, MD, William Wierda, MD PhD, Nitin Jain, MD, Philip A Thompson, MBBS, Alessandra Ferrajoli, MD

Blood (2016) 128 (22): 5573.

https://doi.org/10.1182/blood.V128.22.5573.5573

Published: 2016

Journal Articles

Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study

Peter Hillmen, Anna Schuh, MD PhD, Toby A. Eyre, MD, John M. Pagel, MD PhD, Jennifer R. Brown, MD PhD, Paolo Ghia, John N. Allan, MD, William Wierda, MDPhD, Ahmed Hamdy, MBBCh, Jane Huang, MD, Raquel Izumi, PhD, Priti Patel, Min Hui Wang, John C. Byrd, MD

Blood (2016) 128 (22): 60.

https://doi.org/10.1182/blood.V128.22.60.60

Published: 2016

Journal Articles

Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study

Koji Sasaki, MD, Susan O'Brien, MD, Farhad Ravandi, MD, Deborah A Thomas, MD, Haim G Moore, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Musa Yilmaz, MD, Tapan Kadia, MD, Rebecca Garris, Guillermo Garcia-Manero, MD, Twilla Victoria Jeanis, RN, Jad Chahoud, MD, Gautam Borthakur, MD, William Wierda, MD PhD, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Elias Jabbour

Blood (2015) 126 (23): 2496.

https://doi.org/10.1182/blood.V126.23.2496.2496

Published: 2015

Journal Articles

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

Blood (2015) 126 (23): 2541.

https://doi.org/10.1182/blood.V126.23.2541.2541

Published: 2015

Journal Articles

Identification of B Cell Receptor Antigens in the Chronic Lymphocytic Leukemia Microenvironment

Elisa ten Hacken, PhD, Thomas Oellerich, MD, Maria Gounari, PhD, Julia Hoellenriegel, MS, Kuan-Ting Pan, PhD, Susan O'Brien, MD, William Wierda, MD PhD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Michael J. Keating, MD, Henning Urlaub, PhD, Paolo Ghia, MD PhD, Jan A. Burger, MD PhD

Blood (2015) 126 (23): 2922.

https://doi.org/10.1182/blood.V126.23.2922.2922

Published: 2015

Journal Articles

Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity

Enli Liu, MD MS, Yijiu Tong, Gianpietro Dotti, MD, Barbara Savoldo, MD, Muharrem Muftuoglu, Kayo Kondo, PhD, Malini Mukherjee, Jordan S. Orange, MD PhD, Catherine Sobieski, Abdullah Alsuliman, Hila Shaim, MD, Nobuhiko Imahashi, MD PhD, Michael J. Keating, MD, Chitra M. Hosing, MD, Nina Shah, MD, William Wierda, MD PhD, Richard Champlin, MD, Elizabeth J. Shpall, MD, Katayoun Rezvani, MDPhD

Blood (2015) 126 (23): 3091.

https://doi.org/10.1182/blood.V126.23.3091.3091

Published: 2015

Journal Articles

Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI)

Mary Akosile, BA, Sherry Pierce, BSN, BA, Mark Brandt, BS, Srdan Verstovsek, MD, Gautam Borthakur, MD, Hagop Kantarjian, MD, Farhad Ravandi, MD, William Wierda, MD PhD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Tapan Kadia, MD, Jan A. Burger, MD PhD, Naveen Pemmaraju, MD, Elias Jabbour, Jorge E. Cortes, MD

Blood (2015) 126 (23): 1587.

https://doi.org/10.1182/blood.V126.23.1587.1587

Published: 2015

Journal Articles

Ruxolitinib Reduces Cytokine/Chemokine Levels and Improves Fatigue and Chronic Lymphocytic Leukemia (CLL)-Related Symptoms in CLL Patients Not Requiring Systemic Therapy

Preetesh Jain, MBBS,MDDM,PhD, Michael J. Keating, MD, Charles Cleeland, Sarah Renner, Huang Xuelin, Graciela Nogueras Gonzalez, David M. Harris, William Wierda, MD PhD, Courtney DiNardo, MD, Naveen Pemmaraju, Nitin Jain, MD, Philip Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, Zeev Estrov, MD

Blood (2015) 126 (23): 2943.

https://doi.org/10.1182/blood.V126.23.2943.2943

Published: 2015

Journal Articles

Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia

Candida Vitale, MD, Maria Ciccone, MD, Christina Hinojosa, Michael Keating, MBBS, Naveen Pemmaraju, MD, Susan O'Brien, MD, William Wierda, MD PhD, Deborah A Thomas, MD, Gautam Borthakur, MD, Maro Ohanian, DO, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD

Blood (2015) 126 (23): 5292.

https://doi.org/10.1182/blood.V126.23.5292.5292

Published: 2015

Journal Articles

The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile

Blood (2015) 126 (23): 831.

https://doi.org/10.1182/blood.V126.23.831.831

Published: 2015

Journal Articles

Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies

Nitin Jain, MD, Qiushi Chen, Turgay Ayer, PhD, Susan M. O'Brien, MD, Michael Keating, MBBS, William Wierda, MD PhD, Hagop M. Kantarjian, MD, Chhatwal Jagpreet, PhD

Blood (2015) 126 (23): 871.

https://doi.org/10.1182/blood.V126.23.871.871

Published: 2015

Journal Articles

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Blood (2015) 126 (23): LBA-6.

https://doi.org/10.1182/blood.V126.23.LBA-6.LBA-6

Published: 2015

Journal Articles

Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy

Jeffrey Jones, MD, Anthony R. Mato, MD, Steven Coutre, MD, William Wierda, MD PhD, Michael Y. Choi, MD, Matthew S. Davids, MD, Nicole Lamanna, MD, Paul Barr, MD, Kim Burns, BA, Nicholas Montalvo, MBA, Ming Zhu, PhD, Todd Busman, MS, Jalaja Potluri, MD FACP, Rod A. Humerickhouse, MD PhD, John C. Byrd, MD

Blood (2015) 126 (23): 715.

https://doi.org/10.1182/blood.V126.23.715.715

Published: 2015

Journal Articles

Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells

Uri Rozovski, MD, David M. Harris, Ping LI, PhD, Zhiming Liu, Alessandra Ferrajoli, MD, Jan A Burger, MD PhD, Philip Thompson, MBBS, Nitin Jain, MD, William Wierda, MD PhD, Michael Keating, MBBS, Zeev Estrov, MD

Blood (2015) 126 (23): 4125.

https://doi.org/10.1182/blood.V126.23.4125.4125

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience

Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

Solid Tumors in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Lenalidomide Therapy: Distribution and Clinical Outcomes

Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study

Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

Identification of B Cell Receptor Antigens in the Chronic Lymphocytic Leukemia Microenvironment

Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity

Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI)

Ruxolitinib Reduces Cytokine/Chemokine Levels and Improves Fatigue and Chronic Lymphocytic Leukemia (CLL)-Related Symptoms in CLL Patients Not Requiring Systemic Therapy

Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia

The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile

Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy

Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only